Cancer Res: A double-edged sword in the human body! This substance is too high to increase the risk of cancer!

Insulin-like growth factor-I (IGF-I), an active protein peptide necessary for growth hormone to function in the human body, can promote normal cell proliferation, differentiation and growth, inhibit apoptosis, but also has insulin-like metabolic activity and immunomodulation.
can be counterproductive when there is an imbalance in the level of the body and the regulatory process, leading to cancer.
studies have found a positive correlation between IGF-I concentrations and the risk of colorectal, breast and prostate cancer, but not lung cancer risk.
but the role of IGF-I in other cancer developments, including less common ones, remains unknown.
A recent study of nearly 400,000 participants and 30 cancers found a significant positive correlation between elevated levels of IGF-1 and increased risk of thyroid, multiple myeloma and malignant melanoma, as well as further evidence of its link to breast, prostate and colorectal cancers.
was carried out by a team from the University of Oxford in the UK and the International Agency for Research on Cancer in Lyon, France, and published in Cancer Research.
researchers recruited 394,388 participants (aged between 39 and 73) from the UK Biobank database, recorded information on their height, weight, education level, race and other covariating variables, and collected non-empty blood samples for serum concentration measurements of IGF-1.
also measured serum C-reactive protein, glycation of hemoglobin, sex hormone binding globulin and testosterone concentration.
and continued to record cancer events in the population during follow-up.
23,412 participants (5.9%) were newly diagnosed with various types of malignancies during an average of 6.9 years of follow-up.
the average circulatory IGF-1 concentration was 21.6nmol/L, with higher concentrations of IGF-I in younger and taller black participants than in white people.
the baseline characteristics of the study participants used the Cox proportional risk regression model to assess the correlation between baseline IGF-I concentrations and the development of different cancers.
after adjusting the covariative variables, higher serum IGF-I concentrations (per 5 nmol / l) and thyroid cancer (risk ratio 1.18 HR), multiple myeloma (HR=1.13), female There was a clear positive correlation between the risk of breast cancer (HR=1.11), prostate cancer (HR=1.08), colorectal cancer (1.08), and malignant melanoma (1.07).
high concentrations of IGF-I have a higher risk ratio for different cancers (HRs) (n-394388) and higher serum IGF-I concentrations and liver cancer (HR-0.32), There was a negative correlation between the risk of esophageal squamous cell carcinoma (HR=0.78), ovarian cancer (HR=0.85) and oral cancer (HR=0.88).
sensitivity analysis and adjustment of serum concentrations of C-reactive proteins, glycated hemoglobin, sex hormone-binding globulins and testosterone, qualitatively similar results were produced.
As in this new study, we expanded the range of cancers studied to determine the link between elevated IGF-I levels in this population and increased risk of thyroid cancer, as well as previous studies," said Anika Knuppel, author of the study, which analyzed the risk ratio of high concentrations of IGF-I to different cancers based on follow-up time (HRs) (A: 3.89 years, B: 3.89 years old).
found no association between elevated IGF-1 levels and the risk of lung, bladder, pancreatic, endometrial and kidney cancers.
since the sample supply had not yet been diagnosed with cancer when measuring IGF-1, it is likely that elevated IGF-1 played a role in later cancer development.
, the results suggest that reducing levels of the growth hormone IGF-1 through lifestyle interventions may reduce the risk of a range of cancers, although this strategy requires further study.
.